Signal Genetics (NASDAQ: MGEN) and BG Medicine (NASDAQ:BGMD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.
This table compares Signal Genetics and BG Medicine’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for Signal Genetics and BG Medicine, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Signal Genetics presently has a consensus target price of $16.67, indicating a potential upside of 76.37%. Given Signal Genetics’ higher possible upside, equities research analysts plainly believe Signal Genetics is more favorable than BG Medicine.
Earnings & Valuation
This table compares Signal Genetics and BG Medicine’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Signal Genetics||$3.02 million||66.97||-$20.05 million||N/A||N/A|
|BG Medicine||$1.57 million||0.35||-$4.39 million||N/A||N/A|
BG Medicine has higher revenue, but lower earnings than Signal Genetics.
Insider and Institutional Ownership
16.5% of Signal Genetics shares are held by institutional investors. 44.4% of Signal Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Signal Genetics beats BG Medicine on 7 of the 10 factors compared between the two stocks.
About Signal Genetics
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
About BG Medicine
BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners’ automated platforms. The Company’s CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Receive News & Ratings for Signal Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.